{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-007193","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2026-09-16T20:05:25+00:00","discovered_at":"2026-09-16T20:06:00.315106+00:00","generated_at":"2026-09-16T20:06:05.789108+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sunshine Biopharma majority owner approves reverse split up to 1-for-20","bullets":["Dr. Steve N. Slilaty, CEO, holding ~97% voting power, approved reverse split via written consent on Sept 15, 2026.","Board authorized to effect split at ratio up to 1-for-20, with exact whole-number ratio at board's discretion.","Consent effective 20 days after definitive information statement mailed to stockholders.","Split applies to common stock (SBFM); warrants (SBFMW) also listed on Nasdaq.","No timeline for board decision; action allows flexibility to meet listing requirements."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-007193","json":"https://secwatch.observer/filing/0001683168-26-007193.json","markdown":"https://secwatch.observer/filing/0001683168-26-007193.md","text":"https://secwatch.observer/filing/0001683168-26-007193.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826007193/0001683168-26-007193-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826007193/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-16T20:06:05.789108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}